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The majority of women with HER2-positive 
breast cancer will initially respond to trastuzumab and/
or other HER2-targeted therapies such as pertuzumab, 
lapatinib, neratinib and trastuzumab emtansine (T-DM1). 
However, most will ultimately become resistant to first- 
and later-line therapies, eventually developing metastasis. 
Unfortunately, in spite of significant research efforts, no 
predictive biomarkers of resistance have been clinically 
validated [1]. In fact, despite all our efforts, HER2-positive 
metastatic breast cancer remains an almost always deadly 
disease. Therefore, there is an urgent need for identifying 
new agents able to overcome acquired resistance to HER2-
targeted therapies.
The tumor microenvironment is an ecosystem 
composed of a variety of cell types (e.g., cancer cells, 
fibroblasts, immune cells, endothelial cells). It is now well 
established that understanding the complexity of the tumor 
microenvironment is crucial, since it plays a key role in 
cancer progression, metastasis, and response to therapies 
[2]. Stromal fibroblasts are abundant in breast tumors’ 
microenvironment and are in constant communication with 
cancer cells, either via direct cell–cell contact or through 
the secretion of soluble factors able to activate multiple 
signaling pathways in tumor cells. Actually, soluble factors 
stemming from tumor associated fibroblasts (TAFs) have 
been shown to modulate drug resistance [2]. Improving 
patients’ treatment requires a better understanding of the 
mechanisms leading to resistance to currently existing 
anti-HER2 agents and a deeper comprehension of the role 
played by the microenvironment-tumor crosstalk.
To that end, we have developed several cellular 
models of resistance to trastuzumab and lapatinib to study 
the influence of fibroblasts on the response to HER2-
targeted therapies. Our aim has been to identify new 
therapeutic targets and biomarkers of acquired resistance. 
In our recent paper published in Clinical Cancer Research 
we have described that TAFs promote HER2-targeted 
therapy resistance through FGFR2 activation in breast 
cancer cells [3] (Figure 1). This activation is mediated 
by the production of soluble FGF5 by the neighboring 
fibroblasts (Figure 1). We have also described that breast 
cancer resistance is fueled by HER2 oncogenic addiction. 
HER2 will remain active in the resistant cells through 
FGF5/FGFR2 transactivation via c-SRC [3] (Figure 1). 
Moreover, we also found that resistant cells secrete 
factors that promote fibroblasts activation generating a 
positive feedback loop that drives resistance. Furthermore, 
the coevolution of sensitive breast cancer cells and 
TAFS in vivo also recapitulates the unveiled crosstalk, 
promoting the selection of a more aggressive and resistant 
populations, which might also be responsible for future 
recurrences at secondary organs [3] (Figure 1).
 In agreement with our results, several other 
reports have also proposed that TAFs play an important 
role in the development of resistance to HER2-targeted 
therapies in breast cancer [4, 5]. A recent report by 
Zervantonakis et al. (2020) has described that fibroblast-
secreted factors induce survival in response to lapatinib 
and its combination with either MTOR, BCL-2/XL, or 
MCL-1 inhibitors restores lapatinib drug sensitivity [6]. 
Interestingly, in our study the use of FGFR2 inhibitors 
induced apoptosis in the resistant population inhibiting 
HER2 phosphorylation, and therefore resensitizing cells 
to HER2-targeted therapies both in vitro and in vivo. 
Hence, our results point out the combination of FGFR2 
inhibitors and HER2-targeted drugs as a rational approach 
to sensitize fibroblast-protected HER2+ breast tumors to 
HER2-targeted therapies, by shortcutting the TAF/breast 
cancer cells interplay. In recent years, other studies have 
linked FGFRs activation to HER2-targeted therapies’ 
resistance, not only in breast cancer but also in gastric and 
esophageal cancer [7–9]. These has whipped up interest 
in testing the combination of FGFR inhibitors with HER2 
targeted therapies in the clinical practice. For instance, 
FiGhTeR trial is a phase II trial that aims to assess the 
safety and activity of the FGFR (1, 2 and 3) inhibitor 
pemigatinib, in HER2-trastuzumab resistant gastric 
cancer patients [10]. To our knowledge, this is the first 
clinical trial testing the combination of HER2 targeted 
therapies and FGFR inhibitors although our preclinical 
studies, among others, strongly suggest that these drug 
combinations may overcome HER2-targeted therapies 
resistance. Hence, we foresee the development of new 
clinical trials testing FGFR inhibitors in patients resistant 
to HER2-targeted therapies. 
Acquired resistance to therapies represent a major 
obstacle towards finding an effective cancer treatment, 
accounting for treatment failure in most cases. Given the 
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lack of accurate biomarkers of response, it is unknown 
which percentage of these failures is due to acquired or 
intrinsic resistance to treatment. A deep look at our findings 
in patients’ cohorts has revealed that, fibroblast composition 
(α-SMA staining), stromal FGF5 and FGFR2 expression 
contribute to poor outcome and correlate with c-Src 
activation in HER2-positive patients [3]. This suggests that 
the TAF/FGF5/FGFR2/c-Src/ HER2 resistance axis that we 
propose is present in breast cancer patients and it could 
potentially be reversed with the use of FGFR inhibitors. 
In terms of response biomarkers, our data also shows that 
in patients treated with neoadjuvant trastuzumab, FGF5 
expression either alone or together with phospho-HER2 
expression correlates with a reduced complete response 
rate, as 98.8% of patients with complete response show low 
levels of FGF5 and phospho-HER2 expression [3]. Thus, 
we have identified a new TAF specific biomarker, FGF5, 
whose expression could be used to predict HER2-targeted 
therapies response. In agreement with our results Cazet 
et al. (2018) has shown that triple negative breast cancer 
cells production of Hedgehog ligand reprograms TAFs to 
provide a supportive niche for the acquisition of a chemo-
resistant phenotype via FGF5 production [11]. Hence, our 
studies and others have unveiled a relevant role for FGF5 
in the stromal regulation of HER2+ cancer cells resistance. 
They also underline FGF5 inhibition or blockade as an 
exciting, new and worth-exploring therapeutic strategy 
for resistant or metastatic HER2 breast cancer, which 
should proceed to prospective assessment in clinical trials. 
Interestingly, the therapeutic efficacy of FGF5 vaccines in 
kidney cancer is being tested in a currently ongoing phase 
II clinical trial [12]. 
Our work provides evidence of the role of TAFs, 
FGF5 and FGFR2 in the resistance to HER2-targeted 
therapies (Figure 1). We have identified FGFR2 and FGF5 
as potential therapeutic targets in resistant HER2-positive 
breast cancer and we propose stromal FGF5 expression 
as a new prognosis biomarker for HER2 positive patients. 
We are now exploring the role of FGFR2 and FGF5 in 
metastatic HER2-positive breast cancer (Figure 1). We 
envision that further efforts towards unraveling the 
role of TAFs/FGF5/FGFR2/HER2 axis in cancer cell 
dissemination, colonization, and regulation of stemness 
will help us blunt or prevent metastasis by improving 
HER2-positive breast cancer patients’ treatment options 
and survival rates. 
Figure 1: Schematic illustration depicting the crosstalk between tumor activated fibroblasts and breast cancer cells. 
Breast cancer cells recruit healthy stroma fibroblasts and activate them. Tumor activated fibroblasts then produce FGF5, that will bind to 
FGFR2 in cancer cells and transactivate HER2 via c-Src. This will promote resistance to HER2 targeted therapies, such as trastuzumab and 
lapatinib. These resistant cells will disseminate and colonize other organs such as lungs leading to metastasis formation. The FGF5/FGFR2/
cSRC/HER2 axis might also promote survival of metastatic cells at secondary organs.
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